Elevate Bio, a new biotechnology holding company, has begun its operations in Cambridge, Massachusetts, it was reported yesterday.
The organisation's aim is to develop a portfolio of cell and gene therapy companies by partnering with top academic researchers, medical centres and entrepreneurs.
The company is supported by USD150m funding raised through a Series A financing round co-led by the MPM Capital-managed UBS Oncology Impact Fund and F2 Ventures. Other investors in the company include EcoR1 Capital, Redmile Group, and Samsara BioCapital. Its business model is structured to build single- and multi-product cell and gene therapy companies by providing scientific founders with centralised bench-to-bedside capabilities such as world-class scientists, drug development and commercialisation expertise, and manufacturing facilities among others.
The firm has founded a single research and development, process development and cGMP manufacturing subsidiary called ElevateBio BaseCamp.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval